Nov 15, 2022 / 04:30PM GMT
Timothy Minton Anderson - Wolfe Research, LLC - MD of Equity Research
Same on Friday and on Wednesday and Thursday this week, we'll have the live conference itself and a smattering of companies from my coverage as well as Justin Lake and Mike Buller. So we're happy right now to have AbbVie with us. Various members of the management team, including Rob Michael, and Jeff Stewart and Scott Reents and Neil Gallagher as well as Liz Shea from Investor Relations, and it's going to be a fireside chat discussion. And with that, we're going to go ahead and just jump right in. We've got a lot of content to cover.
So welcome, everyone. Maybe high-level questions first. We'll get to Humira that will be a source of many questions. But outside of Humira, can you just talk about the pushes and pulls that you see in 2023 unrelated to Humira.
Robert A. Michael - AbbVie Inc. - Vice Chairman & President
Sure. Thanks. It's very nice to be with you today. I'd say outside of Humira, obviously, we'll talk about quite a bit. I mean, clearly, in terms of pushes and pulls, I
Abbvie Inc at Wolfe Research Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot